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Introduction
Oral lichen planus (OLP) is a T-cell-mediated chronic inflam-matory oral mucosal disease of unknown etiology. OLP
lesions contain few B-cells or plasma cells and minimal deposits
of immunoglobulin or complement. There are no consistent
serological changes associated with OLP. The oral mucosa in
OLP is highly accessible for detailed investigation. Hence, OLP
is ideally positioned for the study of human T-cell-mediated
inflammation and autoimmunity. Our research over the past 10
years has focused on three basic questions: (i) Why and how do
T-cells accumulate in the superficial lamina propria in OLP? (ii)
Why and how do T-cells enter the oral epithelium in OLP? and
(iii) What triggers basal keratinocyte apoptosis in OLP? In our
attempts to answer these questions, it became apparent that
both antigen-specific and non-specific mechanisms might be
involved. We now present our data that led to this conclusion
and propose a unifying hypothesis for the pathogenesis of OLP.
Clinical Features of OLP
OLP presents as white striations, white papules, white plaques,
erythema, erosions, or blisters affecting predominantly the buc-
cal mucosa, tongue, and gingivae (Vincent et al., 1990; Silverman
et al., 1991). OLP affects one to two percent of the general adult
population and is the most common non-infectious oral muco-
sal disease in patients referred to Oral Medicine and Oral
Pathology clinics (Axéll and Rundqvist, 1987; Bowers et al.,
2000). OLP affects women more than men at a ratio of approxi-
mately 1.4:1 (Axéll and Rundqvist, 1987). OLP occurs predomi-
nantly in adults over 40, although younger adults and children
may be affected (Vincent et al., 1990; Chainani-Wu et al., 2001).
Lesions are usually bilateral, and atrophic and erosive lesions
are often sensitive or painful (Scully and El-Kom, 1985; Eisen,
1993). There may be co-incident skin lesions that present typi-
cally as flat-topped violaceous papules affecting the wrists,
ankles, and genitalia. Nail involvement results in pitting, ptery-
gium formation, and permanent nail loss. Scalp involvement
results in scarring alopecia (Sugerman et al., 2000a). Rarely, there
is laryngeal, esophageal, and conjunctival involvement (Eisen,
1999). There is ongoing concern that OLP may be pre-malig-
nant, although the malignant transformation data are currently
under review, and further prospective studies are required. In
patients who do not use tobacco products, squamous cell carci-
noma (SCC) may arise at the site of a pre-existing OLP lesion in
less than five percent of cases, most frequently in atrophic, ero-
sive, and plaque lesions. Hence, OLP patients are at slightly
increased risk of oral cancer, although it is unlikely that OLP is
inherently pre-malignant (Eisenberg, 2000; Silverman, 2000).
Oral mucosal lichenoid lesions sometimes follow (with a
variable lag period) the administration of a systemic drug.
These lichenoid drug reactions may be unilateral but other-
wise appear as idiopathic OLP. Drugs that have been implica-
ted in oral lichenoid drug reactions include non-steroidal anti-
inflammatory drugs, angiotensin-converting enzyme
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inhibitors, and beta-blockers, although there are many others
(Porter and Scully, 2000). Oral mucosal lichenoid lesions may
follow the placement of a dental restoration or provision of a
denture, again with a variable lag period. These lichenoid con-
tact sensitivity reactions are usually in contact with (or close
to) an amalgam or composite resin dental restoration or a den-
ture component (Lind, 1988; Bolewska et al., 1990). Flavorings,
especially cinnamates in toothpaste, may also trigger lichenoid
contact sensitivity reactions, although there is little published
evidence in support of this observation (Miller et al., 1992;
Yiannias et al., 2000). Circumstantial evidence implicates vari-
ous bacteria and viruses in the etiology of OLP, although any
causal role remains speculative (Scully et al., 1998).
Histology of OLP
The histology of OLP is characterized by a dense subepithelial
lympho-histiocytic infiltrate, increased numbers of intra-epithe-
lial lymphocytes, and degeneration of basal keratinocytes.
Degenerating basal keratinocytes form colloid (Civatte, hyaline,
cytoid) bodies that appear as homogenous eosinophilic glob-
ules. The ultrastructure of colloid bodies suggests that they are
apoptotic keratinocytes, and recent studies using the end-label-
ing method demonstrated DNA fragmentation in these cells
(Hashimoto, 1976; Weedon, 1980; Dekker et al., 1997; Shimizu et
al., 1997; Bloor et al., 1999; Neppelberg et al., 2001). Epithelial
basement membrane changes are common in OLP and include
breaks, branches, and duplications (Jungell et al., 1989a; Zhou et
al., 2001). In addition, the basal keratinocyte anchoring elements
(hemidesmosomes, filaments, and fibrils) are disrupted in OLP
(Haapalainen et al., 1995). Degeneration of basal keratinocytes
and disruption of the epithelial basement membrane and basal
keratinocyte anchoring elements in OLP produce weaknesses at
the epithelial-connective tissue interface which may result in
histological cleft formation (Max-Joseph space) and, rarely, clin-
ical blistering of the oral mucosa (bullous lichen planus).
Parakeratosis, acanthosis, and “saw-tooth” rete peg formation
may be seen. B-cells and plasma cells are infrequent in OLP, and
immunoglobulin and complement deposits are not a consistent
feature. Some cases show fibrinogen and fibrin deposition in a
linear pattern in the basement membrane zone. Colloid bodies
may be positive for fibrin, IgM, C3, C4, and keratin. Laminin
and fibronectin staining may be absent in areas of heavy fibrin
deposition and colloid body formation, suggesting basement
membrane damage in these areas. Immunofluorescent findings
in OLP are not diagnostic (Scully et al., 1998).
Antigen Specificity in OLP
CD8+ T-CELLS
The lymphocytic infiltrate in OLP is composed almost exclu-
sively of T-cells, and the majority of T-cells within the epithe-
lium and adjacent to damaged basal keratinocytes are activat-
ed CD8+ lymphocytes (Matthews et al., 1984; Kilpi, 1987, 1988;
Jungell et al., 1989b). In our recent studies, the majority of
subepithelial and intra-epithelial lymphocytes in OLP were
CD8+ (Khan et al., 2001, submitted). We also observed CD8+ T-
cells that co-localized with apoptotic keratinocytes in OLP
lesions (Sugerman et al., 2000a; Khan et al., 2001, submitted).
Analysis of these data suggests that CD8+ T-cells are involved
in disease pathogenesis, and that activated CD8+ T-cells may
trigger keratinocyte apoptosis in OLP. T-cell lines and clones
isolated in vitro from lichen planus lesions were more cytotox-
ic against autologous lesional keratinocytes than T-cell lines
and clones from the clinically normal skin of lichen planus
patients (Sugerman et al., 2000b). Lesional T-cell clones were
more cytotoxic against autologous lesional keratinocytes and
normal skin keratinocytes than against autologous B-cell
blasts. The majority of cytotoxic clones from lichen planus
lesions were CD8+, and the majority of non-cytotoxic clones
were CD4+. The cytotoxic activity of CD8+ lesional T-cell
clones was partially blocked with anti-MHC class I monoclon-
al antibody (Sugerman et al., 2000b). Hence, early in OLP
lesion formation, CD8+ lesional T-cells may recognize an anti-
gen associated with MHC class I on lesional keratinocytes.
Following antigen recognition and activation, CD8+ cytotoxic
T-cells may trigger keratinocyte apoptosis. T-cell activation
and subsequent clonal expansion may underlie restricted T-
cell receptor Vb gene expression (especially Vb22 and Vb23)
by infiltrating T-cells in OLP (Zhou et al., 1996). Activated
CD8+ T-cells (and possibly keratinocytes) may release
chemokines that attract additional lymphocytes and other
immune cells into the developing OLP lesion (Yamamoto et al.,
1994; Yamamoto and Osaki, 1995). In cutaneous lichen planus,
a dermal infiltrate of T-lymphocytes preceded histological
epithelial damage. In slightly more advanced lesions, lympho-
cytes were seen within the lower epidermis, and at this stage,
there was evidence of epithelial damage, including vacuolar
alteration of basal keratinocytes and slight spongiosis in the
spinous zone (Ragaz and Ackerman, 1981). These findings are
consistent with the current hypothesis that intra-epithelial
CD8+ T-cells trigger keratinocyte apoptosis in OLP.
INITIAL APPROXIMATION BETWEEN
CD8+ T-CELLS AND KERATINOCYTES
Previous studies identified various biochemical changes asso-
ciated with altered keratinocyte antigen expression and altered
keratinocyte function early in lichen planus lesion formation
(Black and Wilson-Jones, 1972; Heyden et al., 1974; Holmstrup
and Dabelsteen, 1979). The authors suggested that these epithe-
lial changes were initial events in disease pathogenesis.
Following altered keratinocyte antigen expression, an antigen-
specific CD8+ T-cell may be either (i) on routine surveillance in
the epithelium and encounter the keratinocyte antigen by
chance (“chance encounter” hypothesis) or (ii) attracted to the
epithelium, along with T-cells of irrelevant specificity, by ker-
atinocyte-derived chemokines (“directed migration” hypothe-
sis). The “chance encounter” hypothesis is supported by find-
ings of CD8+ T-cells in normal human epidermis (Bos et al.,
1987; Spetz et al., 1996) and basal cell degeneration in the
absence of a dense inflammatory infiltrate in lichen planus
lesions (Sarkany and Gaylarde, 1971). The “chance encounter”
hypothesis may explain the prevalence of OLP in the general
population (one to two percent) and the onset of OLP in later
life, i.e., it takes some time for the CD8+ T-cell to encounter its
specific antigen in the oral epithelium. Conversely, the “direct-
ed migration” hypothesis is supported by findings of constitu-
tive chemokine receptor expression on naïve T-cells (Sallusto et
al., 1998) and a dermal T-cell infiltrate prior to the appearance
of intra-epithelial lymphocytes and epithelial damage in lichen
planus lesions (Ragaz and Ackerman, 1981). In addition, pre-
activation of antigen-specific CD8+ T-cells (e.g., in a regional
lymph node) may up-regulate inflammatory chemokine recep-
tor expression and facilitate antigen-specific CD8+ T-cell migra-
tion to the future OLP lesion site (Walsh et al., 1990b). The
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“directed migration” hypothesis predicts that keratinocyte-
derived chemokines attract T-cells of irrelevant specificity
along with antigen-specific T-cells into the developing OLP
lesion. In support of this hypothesis, our recent studies identi-
fied a significant proportion of non-clonal OLP lesional T-cells
(Zhou et al., 1996), and not all CD8+ lesional T-cell clones were
cytotoxic against autologous lesional keratinocytes in vitro
(Sugerman et al., 2000b). In summary, the initial event in OLP
lesion formation may be keratinocyte antigen expression in
association with MHC class I at the future lesion site, with or
without up-regulated keratinocyte chemokine production.
Pioneer antigen-specific CD8+ cytotoxic T-cells may enter the
oral epithelium on routine surveillance, or they may be attract-
ed by keratinocyte-derived chemokines. Subsequently, anti-
gen-specific CD8+ cytotoxic T-cells trigger apoptosis of basal
keratinocytes. In this context, keratinocyte antigen expression
and chemokine production are primary events in OLP lesion
formation, followed by keratinocyte apoptosis triggered by
antigen-specific CD8+ cytotoxic T-cells. Formation of the dense
subepithelial lympho-histiocytic infiltrate and epithelial base-
ment membrane changes in OLP may result from antigen-spe-
cific interactions between keratinocytes and T-cells, or they
may be epiphenomena associated with the recruitment of T-
cells with irrelevant specificity into the OLP lesion site. The
roles of keratinocyte-derived chemokines and lymphocyte
chemokine receptor expression in OLP lesion formation are
currently under investigation.
IDENTITY AND LOCATION OF
THE LICHEN PLANUS ANTIGEN
The lichen planus antigen is unknown, although the antigen
may be a self-peptide, thus defining lichen planus as a true
autoimmune disease. The role of autoimmunity in disease
pathogenesis is supported by many autoimmune features of
OLP, including disease chronicity, adult onset, female predilec-
tion, association with other autoimmune diseases, occasional
tissue-type associations, depressed immune suppressor activi-
ty in OLP patients, and the presence of auto-cytotoxic T-cell
clones in lichen planus lesions (Sugerman et al., 1992, 1993,
2000b). We suggest that keratinocytes express a lichen planus
antigen but only at the lesion site, i.e., the clinical distribution
of lichen planus lesions is determined by the distribution of
the lichen planus antigen. Hence, an early event in lichen
planus lesion formation may be keratinocyte antigen expres-
sion or unmasking at the future lesion site induced by sys-
temic drugs (lichenoid drug reaction), contact allergens in den-
tal restorative materials or toothpastes (contact hypersensitiv-
ity reaction), mechanical trauma (Koebner phenomenon), bac-
terial or viral infection, or an unidentified agent. Subsequently,
intra-epithelial CD8+ cytotoxic T-cells recognize the lichen
planus antigen associated with MHC class I on lesional ker-
atinocytes and trigger keratinocyte apoptosis.
HEAT-SHOCK PROTEINS
We and others identified up-regulated heat-shock protein (HSP)
expression by OLP lesional keratinocytes in situ (Bramanti et al.,
1995; Sugerman et al., 1995; Chaiyarit et al., 1999). We also iden-
tified HSP-reactivity of OLP lesional T-cells in vitro (Sugerman
et al., 1995). Keratinocyte HSP expression in OLP may be an
epiphenomenon associated with pre-existing inflammation.
Alternatively, up-regulated HSP expression by oral mucosal
keratinocytes may be a common final pathway linking a variety
of exogenous agents (systemic drugs, contact allergens,
mechanical trauma, bacterial or viral infection) in the pathogen-
esis of OLP. In this context, HSP expressed by oral keratinocytes
may be auto-antigenic in OLP (Sugerman et al., 1995).
Susceptibility to OLP may result from dysregulated HSP gene
expression by stressed oral keratinocytes or from an inability to
suppress an immune response following self-HSP recognition.
The latter mechanism seems likely, given our finding of
depressed immunological suppressor activity in OLP patients
(Sugerman et al., 1992). However, in vitro examination of the
kinetics of HSP expression by heat-shocked oral mucosal ker-
atinocytes in OLP patients may reveal an alternative or addi-
tional explanation for OLP susceptibility. Of further interest,
both murine (Bensaude and Morange, 1983; Ullrich et al., 1986)
and human (Fisch et al., 1990; Kaur et al., 1993) transformed cell
lines and human malignant lesions (Ciocca et al., 1993; Kimura
et al., 1993) express constitutively high levels of HSP. Hence,
some cases of malignant transformation of OLP lesions may
actually represent an initial lichenoid response to pre-existing
tumor cells expressing elevated levels of HSP, followed by the
development of overt clinical and histological malignancy.
MECHANISMS OF KERATINOCYTE KILLING
Currently, the mechanisms used by CD8+ cytotoxic T-cells to
trigger keratinocyte apoptosis in OLP are unknown. Possible
mechanisms include (i) T-cell-secreted TNF-a binding TNF-a
receptor 1 (TNF R1) on the keratinocyte surface, (ii) T-cell sur-
face CD95L (Fas ligand) binding CD95 (Fas) on the ker-
atinocyte surface, or (iii) T-cell-secreted granzyme B entering
the keratinocyte via perforin-induced membrane pores. All of
these mechanisms may activate the keratinocyte caspase cas-
cade, resulting in keratinocyte apoptosis (Sugerman et al.,
2000a). We identified elevated levels of TNF-a in the serum of
OLP patients and showed that OLP lesional T-cells contained
mRNA for TNF-a and secreted TNF-a in vitro (Sugerman et al.,
1996; Simark-Mattsson et al., 1999; Khan et al., 2001, submitted).
TNF-a was expressed by T-cells throughout the subepithelial
infiltrate and by T-cells adjacent to basal keratinocytes in OLP
lesions. The TNF-a receptor TNF R1 was expressed by basal
and suprabasal epithelial cells in OLP lesions (Khan et al., 2001,
submitted). Hence, T-cell-secreted TNF-a may be involved in
the pathogenesis of OLP. CD8+ cytotoxic T-cells in OLP may
secrete TNF-a that triggers keratinocyte apoptosis via TNF R1.
CD4+ T-CELLS
While the majority of intra-epithelial lymphocytes in OLP are
CD8+ cytotoxic T-cells, most lymphocytes in the lamina propria
are CD4+ helper T-cells (Matthews et al., 1984; Ishii, 1987; Kilpi,
1988). Our previous studies identified mixed helper and sup-
pressor activity among OLP lesional T-cell clones in vitro, sug-
gesting that the balance between immunological help and sup-
pression may determine the clinical behavior of the disease
(Sugerman et al., 1994). We also isolated non-cytotoxic CD4+ T-
cell clones from cutaneous lichen planus lesions in vitro
(Sugerman et al., 2000b). Hence, an early event in OLP lesion for-
mation may be MHC class II antigen presentation to CD4+
helper T-cells, followed by keratinocyte apoptosis triggered by
CD8+ cytotoxic T-cells. MHC class II antigen presentation in OLP
may be mediated by Langerhans cells (LCs) or keratinocytes.
There are increased numbers of LCs in OLP lesions with up-reg-
ulated MHC class II expression (Rich and Reade, 1989; Farthing
et al., 1990). Keratinocytes in OLP also express MHC class II
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(Farthing and Cruchley, 1989; Walsh et al., 1990a). High levels of
antigen expression, CD40 and CD80 expression, and IL-12 secre-
tion by MHC class II+ antigen-presenting cells (APC) in OLP
may promote a T-helper-1 (Th1) CD4+ T-cell response with IL-2
and IFN-g secretion (Constant and Bottomly, 1997). In support of
this hypothesis, human epidermal LCs and keratinocytes are
capable of producing IL-12 (Muller et al., 1994; Kang et al., 1996).
In addition, we identified IFN-g expression by T-cells adjacent to
basal keratinocytes in OLP lesions and IFN-g gene expression
and protein secretion by OLP lesional T-cells in vitro (Simark-
Mattsson et al., 1999; Khan et al., 2001, submitted). A previous
study identified IFN-g gene expression by lymphocytes adjacent
to the epithelial basement membrane in OLP in situ (Simark-
Mattsson et al., 1998). Analysis of these data together suggests
that LCs or keratinocytes in OLP may present antigen associated
with MHC class II to CD4+ helper T-cells that are stimulated to
secrete the Th1 cytokines IL-2 and IFN-g. Subsequently, CD8+
cytotoxic T-cells may be activated by the combination of (i) anti-
gen associated with MHC class I on basal keratinocytes and (ii)
Th1 CD4+ T-cell-derived IL-2 and IFN-g. Activated CD8+ cyto-
toxic T-cells may then trigger basal keratinocyte apoptosis in
OLP. Local production of IFN-g may maintain keratinocyte
MHC class II expression, thereby contributing to disease chronic-
ity (Morhenn and Wood, 1988; Albanesi et al., 1998).
ONE OR TWO ANTIGENS
Antigens that are presented by MHC class II are processed
through an endosomal cellular pathway. In contrast, antigens
that are presented by MHC class I are processed through a
cytosolic cellular pathway. Hence, the putative antigen pre-
sented by MHC class II to CD4+ helper T-cells in OLP may dif-
fer from that presented by MHC class I to CD8+ cytotoxic T-
cells. Alternatively, a single antigen may gain access to both
the endosomal and cytosolic cellular pathways of antigen pre-
sentation. For example, some viruses encode proteins that are
available for cytosolic processing and expression in associa-
tion with MHC class I. These viral proteins are also present on
the plasma membrane and therefore are available for endoso-
mal processing and expression in association with MHC class
II (Roopenian, 1992). MHC class I antigen presentation alone
may result in a transient cytotoxic T-cell response, as seen in
some oral viral infections and recurrent aphthous stomatitis.
MHC class II antigen presentation alone may generate Th1
CD4+ T-cells. However, in the absence of MHC class I antigen
presentation to CD8+ cells, the IL-2 and IFN-g secreted by the
activated Th1 CD4+ T-cells would be cytotoxically inert. As
discussed below, Th1 cytokine secretion by CD4+ T-cells may
be up-regulated by antigen-stimulated CD8+ T-cells, implying
cross-talk between CD8+ and CD4+ T-cells in OLP. Whether
one antigen or two different antigens are involved in disease
pathogenesis, it is likely that simultaneous antigen presenta-
tion to CD8+ and CD4+ T-cells in the context of MHC class I
and II, respectively, is required to develop persistent T-cell
infiltration and CD8+ cytotoxic T-cell activity in OLP.
TH1 CYTOKINE BIAS
IFN-g and TNF-a were expressed by T-cells in the subepithe-
lial lymphocytic infiltrate in OLP. In addition, OLP lesional T-
cells contained mRNA for IFN-g and TNF-a and secreted IFN-
g and TNF-a in vitro. OLP lesional T-cells did not secrete IL-4,
IL-10, or TGF-b1 in vitro (Simark-Mattsson et al., 1998, 1999;
Khan et al., 2001, submitted). We also identified elevated levels
of TNF-a in the serum of OLP patients (Sugerman et al., 1996).
Clearly, the basis of this CD4+ Th1 cytokine bias in OLP war-
rants further investigation. A role for CD40 and CD80 expres-
sion and IL-12 secretion by MHC class II+ APC should be con-
sidered, as should CD154 (CD40 receptor), CD28 (CD80 recep-
tor), and IL-12 receptor expression, by infiltrating CD4+ T-cells
in OLP (Constant and Bottomly, 1997). Th1 cytokine secretion
by CD4+ T-cells in OLP may also be up-regulated by antigen-
stimulated CD8+ T-cells, i.e., cross-talk between CD8+ and
CD4+ T-cells may further skew the CD4+ T-cell response
toward a Th1 cytokine profile in OLP.
T-cells in the lymphocytic infiltrate in OLP produce and
secrete IFN-g and TNF-a (Simark-Mattsson et al., 1998, 1999;
Khan et al., 2001, submitted). As previously discussed, IFN-g
secretion by Th1 CD4+ T-cells in OLP may stimulate TNF-a
secretion by CD8+ cytotoxic T-cells which triggers keratinocyte
apoptosis. Blockade of IFN-g (Debray-Sachs et al., 1991; Nicoletti
et al., 1997; Prud’homme and Chang, 1999; Sigidin et al., 2001) or
TNF-a (Piguet et al., 1992; Williams et al., 1992; Elliott et al., 1993,
1994) was therapeutic in human and experimental autoimmuni-
ty and may therefore be effective in the treatment of OLP. Th1
differentiation of CD4+ T-cells leading to IFN-g secretion is stim-
ulated by CD80 (B7-1) expression and IL-12 secretion by MHC
class II+ APC (Constant and Bottomly, 1997). CD80 expression
was up-regulated in multiple sclerosis (MS) plaques, while
blockade of CD80 function was therapeutic in an animal model
of MS (Miller et al., 1995; Windhagen et al., 1995). Recent studies
detected high levels of IL-12 expression in MS plaques and
rheumatoid arthritis (RA) synovia (Windhagen et al., 1995;
Morita et al., 1998). IL-12 administration accelerated diabetes
development and arthritis severity in animal models of insulin-
dependent diabetes mellitus (IDDM) and RA (Trembleau et al.,
1995; Leung et al., 2000). Reduction of IL-12 activity with neu-
tralizing anti-IL-12 antibody or IL-12 p40 (a natural antagonist of
IL-12) significantly reduced clinical disease in animal models of
MS, RA, and IDDM (Leonard et al., 1995; Trembleau et al., 1997;
Malfait et al., 1998; Matthys et al., 1998; Nicoletti et al., 1999; Costa
et al., 2001). Hence, IL-12 may be pathogenic while IL-12 inhibi-
tion may be therapeutic in autoimmune diseases where T-cells
play an important role. Although IL-12 activity in OLP has not
been measured directly, the Th1 cytokine bias in OLP suggests
IL-12 co-stimulation of CD4+ T-cells with subsequent production
of IFN-g. In this context, reduction of IL-12 activity may be of
clinical benefit in OLP. IL-12 production by monocytes, dendrit-
ic cells, and endothelial cells is stimulated by ligation between
cell-surface CD40 and T-cell CD154 (Shu et al., 1995; Cella et al.,
1996; Kelsall et al., 1996; Kennedy et al., 1996; Lienenluke et al.,
2000). IL-12 secretion stimulated by CD40-CD154 ligation is
implicated in MS and RA (Gerritse et al., 1996; Balashov et al.,
1997; MacDonald et al., 1997; Sekine et al., 1998). Disruption of
CD40-CD154 interaction was preventive or therapeutic in ani-
mal models of MS, RA, and IDDM (Durie et al., 1993; Gerritse et
al., 1996; Balasa et al., 1997; Boon et al., 2001). The role of CD40-
CD154 ligation in OLP is unknown, although disruption of this
interaction may reduce IL-12 secretion by APC and Th1 differ-
entiation of CD4+ T-cells and may thus be therapeutic in OLP.
HYPOTHESIS FOR ANTIGEN PRESENTATION
AND T-CELL ACTIVATION IN OLP
The role of CD8+ T-cells is to seek out and destroy cells express-
ing foreign antigenic peptides in the context of MHC class I.
However, the CD8+ T-cell may require antigen-specific confirma-
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tion from a CD4+ T-cell prior to initiating target cell lysis. Hence,
during OLP lesion formation, the CD8+ T-cell antigen receptor
may engage a specific foreign antigen (Ag 1) in the context of
MHC class I expressed by basal keratinocytes [1] (numbers in
brackets refer to Fig. 1). The CD8+ T-cell may then seek CD4+ T-
cell confirmation by expressing the hypothetical “request cyto-
toxic activity” (RCA) cell-surface molecule [2] or secreting certain
cytokines. The CD4+ T-cell expresses the hypothetical “RCA
receptor” (RCA R) [4], but only following CD4+ T-cell antigen
receptor engagement of a related foreign antigen (Ag 2) in the
context of MHC class II expressed by basal keratinocytes or LCs
[3]. As discussed above, Ag 1 and Ag 2 may be identical or dif-
ferent peptides. If different, it seems reasonable that they should
have a common origin. Ligation between RCA and RCA R in
combination with co-stimulatory signals from the MHC class II+
APC (e.g., CD40, CD80, and IL-12) initiates Th1 differentiation of
the CD4+ T-cell that then secretes IL-2 and IFN-g [5]. Receptors for
IL-2 and IFN-g are expressed by the CD8+ T-cell, but only follow-
ing (i) specific engagement of the CD8+ T-cell antigen receptor in
the context of MHC class I and/or (ii) ligation between RCA and
RCA R. The CD4+ Th1 cytokines (IL-2 and IFN-g) are detected by
the CD8+ T-cell and are interpreted as confirmation to proceed
with target cell (basal keratinocyte) lysis. Recent studies identi-
fied monokine induced by interferon gamma (MIG), interferon
gamma-inducible protein-10 (IP-10), and macrophage chemoat-
tractant protein-1 (MCP-1) chemokine expression by basal ker-
atinocytes in cutaneous lichen planus lesions in situ (Spandau et
al., 1998) and IL-8, MCP-1, and GRO gamma chemokine expres-
sion by IL-1-stimulated human oral keratinocytes in vitro (Bickel
et al., 1996). In addition, oral keratinocytes from patients with
OLP secreted cytokines that up-regulated mononuclear cell adhe-
sion molecule expression and trans-endothelial cell migration in
vitro (Yamamoto et al., 2000). Hence, keratinocyte activation by (i)
the CD4+ or CD8+ T-cell following receptor-antigen-MHC trimer-
ization or (ii) exogenous agents such as viral infection, bacterial
products, mechanical trauma, systemic drugs, or contact sensitiv-
ity may up-regulate keratinocyte cytokine and chemokine secre-
tion [6] that promotes lymphocyte extravasation and directs lym-
phocyte migration into the site of the developing OLP lesion.
This hypothesis predicts that both CD4+ and CD8+ T-cells
must engage related foreign antigens prior to the initiation of
target cell lysis. The presence of both CD4+ and CD8+ auto-
reactive T-cells seems unlikely. Hence, this “two-cell hypothe-
sis” for cell-mediated cytotoxicity provides a level of protec-
tion against devastating cell-mediated autoimmune reactions.
In OLP (and possibly other T-cell-mediated autoimmune dis-
eases), this autoimmune defense mechanism may be overrid-
den by (i) the presence of both CD4+ and CD8+ autoreactive T-
cells, (ii) constitutive Th1 cytokine secretion by CD4+ lesional
T-cells, (iii) Th1 cytokine secretion by the APC (as discussed
above), or (iv) constitutive lytic activity of antigen-specific
CD8+ lesional T-cells. The latter two hypotheses predict that
CD4+ T-cells are not necessary for keratinocyte apoptosis trig-
gered by CD8+ cytotoxic T-cells in OLP. However, the presence
of large numbers of CD4+ T-cells in OLP lesions argues favor-
ably for their involvement in disease pathogenesis.
SUMMARY OF ANTIGEN SPECIFICITY IN OLP
Analysis of these data suggests that many antigen-specific
mechanisms may be involved in the pathogenesis of OLP,
including (i) MHC class I- and MHC class II-restricted antigen
presentation by lesional keratinocytes, (ii) activation of anti-
gen-specific CD4+ helper T-cells and CD8+ cytotoxic T-cells, (iii)
clonal expansion of antigen-specific T-cells, and (iv) ker-
atinocyte apoptosis triggered by antigen-specific CD8+ cytotox-
ic T-cells. However, our recent studies showed that a significant
proportion of OLP lesional T-cells were non-clonal (Zhou et al.,
1996) and that not all CD8+ T-cell clones isolated from lichen
planus lesions were cytotoxic against autologous lesional ker-
atinocytes in vitro (Sugerman et al., 2000b). Other studies found
that many intra-epithelial T-cells in OLP expressed the naïve T-
cell marker CD45RA (Walton et al., 1998). Analysis of these data
suggests that a proportion of T-cells in the OLP lymphocytic
infiltrate are not specific for the lichen planus antigen and are
not activated. As discussed below, non-specific T-cells may be
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Figure 1. Hypothesis for antigen presentation and T-cell activation in
OLP. Initially, the CD8+ T-cell antigen receptor engages a specific foreign
antigen (Ag 1) in the context of MHC class I on the basal keratinocyte
target cell in OLP [1]. The CD8+ T-cell may then seek CD4+ T-cell confir-
mation by expressing the hypothetical “request cytotoxic activity” (RCA)
cell surface molecule [2]. The CD4+ T-cell expresses the hypothetical
“RCA receptor” (RCA R) [4], but only following CD4+ T-cell antigen
receptor engagement of a related foreign antigen (Ag 2) in the context
of MHC class II on the antigen-presenting cell (basal keratinocyte or
Langerhans cell in OLP) [3]. Ligation between RCA and RCA R in com-
bination with co-stimulatory signals from the MHC class II+ antigen-pre-
senting cell (e.g., CD40, CD80, and IL-12 binding CD154, CD28, and
IL-12 R, respectively, on the CD4+ T-cell) initiates Th1 differentiation of the
CD4+ T-cell that then secretes IL-2 and IFN-g [5]. Receptors for IL-2 and
IFN-g are expressed by the CD8+ T-cell, but only following (i) specific
engagement of the CD8+ T-cell antigen receptor in the context of MHC
class I and/or (ii) ligation between RCA and RCA R. The CD4+ Th1
cytokines (IL-2 and IFN-g) are detected by the CD8+ T-cell and interpret-
ed as confirmation to proceed with target cell (basal keratinocyte) lysis.
Keratinocyte activation by (i) the CD4+ or CD8+ T-cell following receptor-
antigen-MHC trimerization or (ii) exogenous agents such as viral infec-
tion, bacterial products, mechanical trauma, systemic drugs, or contact
sensitivity up-regulates keratinocyte cytokine and chemokine secretion
[6] that promotes lymphocyte extravasation and directs lymphocyte
migration into the site of the developing OLP lesion.
attracted to and retained within OLP lesions by various mech-
anisms associated with pre-existing inflammation.
Non-specific Mechanisms in OLP
THE EPITHELIAL BASEMENT MEMBRANE
As discussed above, epithelial basement membrane changes are
common in OLP and include breaks, branches, and duplications
(Jungell et al., 1989a; Zhou et al., 2001). Keratinocytes contribute
to the structure of the epithelial basement membrane by secre-
ting collagen IV and laminin V into the basement membrane
zone (Marinkovich et al., 1993). Presumably, apoptotic ker-
atinocytes are no longer able to perform this function. Hence,
keratinocyte apoptosis triggered by intra-epithelial CD8+ cyto-
toxic T-cells may result in epithelial basement membrane dis-
ruption in OLP. Conversely, evidence from the involuting mouse
mammary gland model suggests that keratinocytes require a
basement-membrane-derived cell survival signal to prevent the
onset of apoptosis (Pullan et al., 1996). Hence, epithelial base-
ment membrane disruption may trigger keratinocyte apoptosis
in OLP. An intriguing question in OLP is which came first — ker-
atinocyte apoptosis or epithelial basement membrane disrup-
tion? Both mechanisms may be involved in the pathogenesis of
OLP, e.g., basement membrane disruption may trigger ker-
atinocyte apoptosis, and apoptotic keratinocytes may be unable
to repair the disrupted basement membrane. Such a cyclical
mechanism may underlie disease chronicity.
MATRIX METALLOPROTEINASES
We recently examined the distribution, activation, and cellular
sources of matrix metalloproteinases (MMPs) in OLP. MMPs are
a family of zinc-containing endo-proteinases with at least 20
members. The principal function of MMPs is the proteolytic
degradation of connective tissue matrix proteins. MMPs share
biochemical properties but retain distinct substrate specificities.
The gelatinases (e.g., MMP-2 and -9) cleave collagen IV, and the
stromelysins (e.g., MMP-3 and -10) cleave collagen IV and
laminin. MMP proteolysis is regulated by the action of endoge-
nous inhibitors, including the tissue inhibitors of metallopro-
teinases (TIMPs), which form stable inactive enzyme-inhibitor
complexes with MMPs or proMMPs. In our preliminary stud-
ies, staining for collagen IV and laminin showed epithelial base-
ment membrane disruption in OLP (Zhou et al., 2001). MMP-2
and MMP-3 were expressed mainly in the OLP epithelium.
MMP-9 was identified within the inflammatory infiltrate in the
lamina propria, with occasional positive cells in the epithelium.
Culture supernatants from OLP lesional T-cells contained a
higher concentration of MMP-9 than those from OLP or healthy
control peripheral blood T-cells. The concentration of TIMP-1,
an inhibitor of MMP-9, followed a similar pattern. All T-cells
contained mRNA for MMP-9 and TIMP-1. Importantly, lesional
T-cell MMP-9 (but not TIMP-1) mRNA levels and protein secre-
tion increased following stimulation with TNF-a. MMP-9 activ-
ity was confirmed by gelatin gel zymography. The in vitro acti-
vation rate of MMP-9 from OLP lesional T-cells was greater than
that from peripheral blood T-cells of OLP patients and healthy
control subjects, suggesting the presence of additional MMP-9
activators in the OLP lesional T-cell supernatants (Zhou et al.,
2001). Hence, T-cells in OLP may be stimulated by TNF-a to
secrete MMP-9. The antigen specificity of these T-cells is
unknown, although non-specific T-cells may be activated in this
manner, thereby amplifying the MMP-9 produced in OLP
lesions. T-cell-secreted MMP-9 may disrupt the epithelial base-
ment membrane in OLP lesions. The disrupted basement mem-
brane in OLP no longer delivers the keratinocyte survival sig-
nal, which may trigger keratinocyte apoptosis. In addition,
MMP-9-induced basement membrane disruption may facilitate
the passage of antigen-specific CD8+ cytotoxic T-cells into the
OLP epithelium, where they trigger further keratinocyte apop-
tosis. TNF-a is synthesized as a 233-amino-acid membrane-
bound precursor protein which is proteolytically cleaved to
yield the mature 157-amino-acid soluble cytokine. Precursor
TNF-a is cleaved by TNF-alpha-converting enzyme (TACE), a
membrane-bound disintegrin metalloproteinase (Gearing et al.,
1994; McGeehan et al., 1994; Black et al., 1997; Moss et al., 1997;
Itai et al., 2001). As previously discussed, we identified TNF-a
secretion by OLP lesional T-cells and various MMPs in OLP.
Hence, an additional role for MMPs in OLP may involve the
release of active TNF-a from OLP lesional T-cells.
MAST CELLS
Our recent studies showed increased mast cell density in OLP
(Zhao et al., 1997). Approximately 60% of mast cells were degran-
ulated in OLP, compared with 20% in normal buccal mucosa
(Zhao et al., 2001). Mast cell degranulation in OLP releases a
range of pro-inflammatory mediators such as TNF-a, chymase,
and tryptase. TNF-a may up-regulate endothelial cell adhesion
molecule (CD62E, CD54, and CD106) expression in OLP that is
required for lymphocyte adhesion to the luminal surfaces of
blood vessels and subsequent extravasation (Klein et al., 1989;
Walsh et al., 1991; Walton et al., 1994). In addition, we identified
clusters of mast cells and intra-epithelial CD8+ T-cells at sites of
basement membrane disruption in OLP (Zhou et al., 2002).
Analysis of these data suggests that mast cells may play a role in
epithelial basement membrane disruption in OLP, and that CD8+
T-cells may migrate through basement membrane breaks to
enter the OLP epithelium. MMPs are secreted as inactive proen-
zymes and are rapidly degraded after activation. Chymase, a
mast cell protease, is a known activator of MMP-9 (Fang et al.,
1997). Hence, basement membrane disruption in OLP may be
mediated by mast cell proteases directly or indirectly via activa-
tion of T-cell-secreted MMP-9 (Zhao et al., 2001; Zhou et al., 2001).
CHEMOKINES
The chemokines are a superfamily of pro-inflammatory cytokines
that are produced by virtually all somatic cells. RANTES (regu-
lated on activation, normal T-cell expressed and secreted) is one
of the most extensively studied chemokines. RANTES is a mem-
ber of the CC chemokine family and is produced by various cells,
including activated T-lymphocytes, bronchial epithelial cells,
rheumatoid synovial fibroblasts, oral keratinocytes, and mast
cells. RANTES plays a critical role in the recruitment of lympho-
cytes, monocytes, natural killer cells, eosinophils, basophils, and
mast cells. Chemokines mediate their biological effects by bind-
ing to cell-surface receptors. Several RANTES receptors have
been identified, including CCR1, CCR3, CCR4, CCR5, CCR9, and
CCR10. The CC chemokines, including RANTES, activate mast
cell migration and degranulation via these G protein-coupled
receptors (Bischoff et al., 1993).
We identified T-cell RANTES expression in OLP in situ
(Zhao et al., 2002). OLP lesional T-cells expressed mRNA for
RANTES, and TNF-a stimulation up-regulated OLP lesional T-
cell RANTES secretion in vitro (Zhao et al., 2001). Mast cells
expressed the CCR1 RANTES receptor in OLP in situ (Zhao et al.,
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2002). An unidentified factor in OLP lesional T-cell supernatant
up-regulated human mast cell line (HMC-1) CCR1 mRNA
expression in vitro (Zhao et al., 2002). OLP lesional T-cell super-
natant stimulated HMC-1 migration in vitro. This effect was par-
tially blocked by anti-RANTES antibody (Zhao et al., 2002). OLP
lesional T-cell supernatant stimulated HMC-1 degranulation in
vitro with release of TNF-a and histamine. This effect was
blocked by anti-RANTES antibody (Zhao et al., 2001). Hence,
RANTES secreted by OLP lesional T-cells may attract mast cells
into the developing OLP lesion and subsequently stimulate mast
cell degranulation. Degranulating mast cells in OLP would
release TNF-a, which up-regulates OLP lesional T-cell RANTES
secretion. Such a cyclical mechanism may underlie OLP chronic-
ity. Furthermore, RANTES induces expression of PI 3-kinase,
which is involved in signal transduction for both chemotaxis and
mitogen-activated protein kinase activation. PI 3-kinase activates
Akt/protein kinase B, an important component of the cell’s pro-
survival machinery (Kane et al., 1999). We identified CCR1
expression by both T-cells and mast cells in OLP (Zhao et al.,
2002). Hence, in addition to stimulating mast cell chemotaxis
and degranulation, RANTES secreted by OLP lesional T-cells
may also prolong the survival of inflammatory cells in OLP and
thereby contribute to disease chronicity. As discussed, a previous
study identified basal keratinocyte expression of another CC
chemokine, MCP-1, and two CXC chemokines, MIG and IP-10,
in cutaneous lichen planus lesions (Spandau et al., 1998).
Analysis of these data suggests that chemokines produced by T-
cells and keratinocytes may attract various inflammatory cells
into the site of the developing OLP lesion. The antigen specifici-
ty of the T-cells recruited in this manner is unknown. However,
constitutive chemokine receptor expression on naïve T-cells
(Sallusto et al., 1998) suggests that such a mechanism may result
in the accumulation of non-specific T-cells in OLP lesions.
SUMMARY OF NON-SPECIFIC MECHANISMS IN OLP
Analysis of these data suggests that many non-specific mech-
anisms may be involved in the pathogenesis of OLP, including
(i) mast cell chemotaxis and degranulation stimulated by T-cell
RANTES, (ii) endothelial cell adhesion molecule expression
stimulated by mast cell TNF-a, (iii) T-cell MMP-9 activation by
mast cell chymase, (iv) epithelial basement membrane disrup-
tion by mast cell proteases or T-cell MMP-9, (v) keratinocyte
apoptosis triggered by epithelial basement membrane disrup-
tion, (vi) intra-epithelial CD8+ T-cell migration through base-
ment membrane breaks, (vii) inflammatory cell survival pro-
longed by T-cell RANTES, and (viii) non-specific T-cell recruit-
ment by keratinocyte-derived chemokines. We suggested pre-
viously that only a small percentage of lymphocytes recruited
to the OLP lesion site are specific for the lichen planus antigen
(Sugerman et al., 2000a). Non-specific T-cells in OLP may con-
tribute to disease pathogenesis by secreting RANTES and
MMP-9, although this remains to be determined.
Deficient Antigen-specific 
Immunosuppression in OLP
In our recent studies, the expression of TGF-b1 in the subepi-
thelial lymphocytic infiltrate in OLP was variable, with regions
of positive and negative expression. The intra-epithelial lym-
phocytes in OLP were all TGF-b1- (Khan et al., 2001, submit-
ted). TGF-b1 inhibits growth and induces differentiation and
apoptosis of keratinocytes in vitro (Flanders and Roberts, 2001).
Hence, T-cell-derived TGF-b1 may play a role in the epithelial
pathology associated with OLP. TGF-b-secreting T-cells were
recognized recently as a distinct population of antigen-specific
CD4+ regulatory T-cells, termed “Th3” (Fukaura et al., 1996).
There is now compelling evidence that antigen-specific CD4+
TGF-b-secreting Th3 regulatory T-cells suppress immune
responses to self-antigens and prevent autoimmunity (Bridoux
et al., 1997; Mason and Powrie, 1998). TGF-b1 exerts its
immunosuppressive effect in part by interfering with antigen
presentation, thereby suppressing effector T-cell proliferation,
differentiation, and cytokine secretion. TGF-b1 down-regulates
APC IL-12 production, thus blocking Th1 differentiation of
CD4+ T-cells, IFN-g secretion, and cytotoxic T-cell responses
(Letterio and Roberts, 1998). TGF-b1 activity is mediated via the
TGF-bII receptor, with subsequent phosphorylation of the
TGF-bI receptor. Both receptors form a heterodimeric complex
that initiates TGF-b1 activity (Massagué, 1998). The role of the
TGF-bIII receptor in TGF-b signaling is currently under inves-
tigation (Blobe et al., 2001). The activated TGF-bI receptor phos-
phorylates cytoplasmic Smad2 or Smad3, which then binds
Smad4. The Smad complex translocates to the nucleus, where it
regulates the transcription of TGF-b response genes. Of interest
in the current context is that mice deficient in TGF-b1 or Smad3
developed widespread autoimmune-like inflammatory dis-
ease, including a periductal lymphocytic infiltrate in the liver,
pancreas, and salivary glands (Shull et al., 1992; Dang et al.,
1995; Yang et al., 1999). Exogenously administered TGF-b1 was
both preventive and therapeutic in animal models of autoim-
mune disease, including experimental allergic
encephalomyelitis and collagen-induced arthritis (Johns et al.,
1991; Kuruvilla et al., 1991; Racke et al., 1991; Thorbecke et al.,
1992). Retroviral transduction of T-cells with TGF-b1 cDNA
significantly delayed the onset of experimental allergic
encephalomyelitis. The transduced T-cells secreted significant
quantities of TGF-b1, and the clinical benefit was negated by
simultaneous injection of anti-TGF-b1 antibody (Chen et al.,
1998). Finally, administration of neutralizing anti-TGF-b1 anti-
bodies exacerbated experimental allergic encephalomyelitis,
suggesting that endogenous TGF-b1 has a regulatory function
in this animal model of MS (Racke et al., 1992; Johns and
Sriram, 1993). Analysis of these data suggests that TGF-b1 defi-
ciency may predispose to autoimmune lymphocytic inflamma-
tion, while TGF-b1 administration may be therapeutic in auto-
immune diseases where T-cells play an important role.
In this context, OLP chronicity may be due, in part, to a
defect in the TGF-b1 immunosuppressive pathway involving (i)
insufficient numbers of TGF-b1-secreting Th3 regulatory T-cells,
(ii) blockage of TGF-b1 secretion, (iii) secretion of non-function-
al TGF-b1, (iv) defective or inadequate TGF-b1 receptor expres-
sion, or (v) defective intracellular signaling downstream from
the TGF-b1 receptors. In our recent studies, the intra-epithelial
lymphocytes in OLP were all TGF-b1-, suggesting insufficient
numbers of regulatory T-cells in the OLP epithelium. We identi-
fied TGF-b1+ T-cells in the subepithelial lymphocytic infiltrate
in OLP, although OLP lesional T-cells did not secrete TGF-b1 in
vitro, suggesting that T-cell TGF-b1 secretion may be blocked in
OLP (Khan et al., 2001, submitted). Importantly, the Th1
cytokine IFN-g inhibits the immunosuppressive activity of
TGF-b1 by blocking TGF-b1-induced phosphorylation of the
Smad3 transcription factor (Ulloa et al., 1999). Hence, the bal-
ance between TGF-b1 and IFN-g signaling may determine the
level of immunological activity in OLP lesions, as has been sug-
gested in other inflammatory mucosal diseases (Strober et al.,
1997). Local overproduction of IFN-g by Th1 CD4+ T-cells in
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OLP lesions would down-regulate the immunosuppressive
effect of TGF-b1 and up-regulate keratinocyte MHC class II
expression and CD8+ cytotoxic T-cell activity.
Breakdown of Immune Privilege in OLP
In recent studies, TNF-a was expressed as a continuous band by
basal epithelial cells, and TNF R1 was expressed by infiltrating
T-cells in OLP (Khan et al., 2001, submitted). Analysis of these
data suggests that, in OLP, keratinocyte-derived TNF-a may
trigger T-cell apoptosis via TNF R1. Hence, disease activity in
OLP may be determined by the balance between keratinocyte
apoptosis triggered by infiltrating T-cells and T-cell apoptosis
triggered by resident keratinocytes. In this context, OLP may
result from a failure of resident keratinocytes to trigger T-cell
apoptosis. Oral keratinocytes in OLP may fail to express enough
active TNF-a, or the release of TNF-a from the surfaces of oral
keratinocytes in OLP may be blocked, possibly due to defective
MMP activity (above). Infiltrating T-cells in OLP may fail to
express enough active TNF R1, or the apoptotic pathway down-
stream of TNF R1 (including TRADD, FADD, and caspases 8, 1,
and 3) may be defective in OLP lesional T-cells. The concept of
inadequate keratinocyte-derived TNF-a-mediated T-cell lysis in
OLP is purely speculative, although supported indirectly by
findings of keratinocyte TNF-a expression in the normal oral
mucosa (Walsh et al., 1995) and skin (Kristensen et al., 1993). In
more general terms, the normal oral mucosa may be an immune-
privileged site, similar to the eye, testis, and placenta. In the eye
and testis, immune privilege is mediated by Fas ligand (CD95L),
expressed by stromal cells, that triggers apoptosis of infiltrating
inflammatory cells expressing Fas (CD95) (Bellgrau et al., 1995;
Griffith et al., 1995). This mechanism is thought to minimize
potentially damaging inflammation in these organs. A similar
mechanism (oral keratinocyte CD95L or TNF-a triggering T-cell
apoptosis via CD95 or TNF R1, respectively) may prevent exces-
sive T-cell infiltration in the normal oral mucosa, while failure of
such a mechanism may result in OLP and possibly other autoim-
mune oral mucosal diseases, including cicatricial pemphigoid
and pemphigus vulgaris. This concept has broad-reaching impli-
cations for many T-cell-mediated autoimmune diseases. MS,
IDDM, Sjögren’s syndrome (SS), and OLP may result from: (i)
inadequate CD95L or TNF-a expression by neural Schwann
cells, pancreatic islet cells, salivary acinar cells, and oral ker-
atinocytes (respectively); (ii) inadequate CD95 or TNF R1
expression by infiltrating T-cells; or (iii) defective T-cell apoptot-
ic pathways downstream from CD95 or TNF R1. A role for CD95
in the prevention of autoimmunity was suggested by the CD95
(lpr) and CD95L (gld) mutations that are associated with sponta-
neous lymphoproliferative autoimmune diseases in mice (Chu et
al., 1993; Takahashi et al., 1994). Such a role for TNF-a in the pre-
vention of autoimmunity has not been identified.
An alternative explanation for these findings is that ker-
atinocyte-derived TNF-a may trigger T-cell apoptosis via TNF
R1 in OLP, although killing may be restricted to immunosup-
pressive T-cells such as those producing TGF-b1. As discussed
above, we showed recently that intra-epithelial T-cells in OLP
did not express the immunosuppressive cytokine TGF-b1, sug-
gesting unchecked immunological activity within the OLP
lesional epithelium (Khan et al., 2001, submitted). Selective lysis
of intra-epithelial TNF R1+ TGF-b1+ immunosuppressive T-cells
by keratinocyte-derived TNF-a may promote disease activity in
OLP. This hypothesis suggests that the apoptotic pathway (TNF
R1, TRADD, FADD, and caspases 8, 1, and 3) is fully functional
in immunosuppressive T-cells yet non-functional in cytotoxic T-
cells in OLP. Furthermore, many T-cell-mediated autoimmune
diseases (including MS, IDDM, SS, and OLP) may be associated
with up-regulated TNF R1 or CD95 expression and apoptosis of
TGF-b1+ immunosuppressive T-cells, resulting in unchecked
immunological activity at the autoimmune lesion site. We also
identified weak keratinocyte TGF-b1 expression in OLP (Khan
et al., 2001, submitted). TGF-b1 is expressed in normal adult
mouse epidermis and papillary dermis and may play a role in
suppressing unwanted immune response in the oral mucosa
and skin (Thompson et al., 1989). TGF-b1 is also secreted by a
variety of tumors and may be involved in the suppression of
anti-tumor immune responses (Gorelik and Flavell, 2001;
Pasche, 2001). In this context, keratinocyte-derived TGF-b1-
mediated immunosuppression may be defective in OLP lesions,
although further studies are required to address this question.
Graft-vs.-Host Disease and OLP
Graft-vs.-host disease (GVHD) is a common serious complica-
tion following allogeneic bone marrow transplantation (BMT).
Most patients who undergo allogeneic BMT receive stem cells
from MHC-identical donors. In these patients, GVHD is initi-
ated by donor T-cells that recognize a subset of host peptides
called minor histocompatibility antigens (miHAs). miHAs are
derived from the expression of polymorphic genes that distin-
guish host from donor. Recent studies have shown that host-
derived, rather than donor-derived, APC initiate GVHD
(Shlomchik et al., 1999). Acute GVHD occurs within the first
100 days of transplantation and consists of the triad of der-
matitis, enteritis, and hepatitis, with immunosuppression and
cachexia. Acute cutaneous GVHD usually starts as scattered
erythematous macules and papules. Erythematous macules
may coalesce to form confluent erythema. Chronic GVHD
develops after day 100 and consists of an autoimmune syn-
drome affecting multiple organs. The skin is the main organ
involved in chronic GVHD and manifests as a lichen-planus-
like eruption or scleroderma (Kuechle, 2001).
Oral involvement occurs in 33% to 75% of patients with acute
GVHD and up to 80% of patients with chronic GVHD (Schubert
and Sullivan, 1990). Oral mucosal GVHD resembles OLP both
clinically and histologically (Fujii et al., 1988; Mattsson et al., 1992).
As with OLP, SCC may develop in oral and cutaneous chronic
GVHD (Otsubo et al., 1997; Gmeinhart et al., 1999). Although the
antigen specificity of lichen planus and mucocutaneous GVHD is
probably distinct, it is likely that they share similar immunologi-
cal effector mechanisms, resulting in T-cell infiltration, basal ker-
atinocyte apoptosis, epithelial basement membrane disruption,
and clinical disease. Hence, research findings in one disease may
give clues to the pathophysiology of the other. The role of TNF-a
as a major effector molecule of GVHD has been confirmed in sev-
eral experimental systems. Importantly, neutralizing anti-TNF-a
antibodies have been shown to alleviate cutaneous and intestinal
GVHD in both mice and humans (Piguet et al., 1987; Herve et al.,
1992; Brown et al., 1999; Stuber et al., 1999). Blockade of the CD40-
CD154 co-stimulatory pathway of antigen presentation prevented
GVHD following allogeneic BMT (Durie et al., 1994; Blazar et al.,
1998; Seung et al., 2000). As discussed previously, CD40-CD154
blockade inhibits APC IL-12 production and Th1 differentiation of
CD4+ T-cells, thereby suppressing cell-mediated immune respons-
es and GVHD. The role of the Fas apoptotic pathway in cutaneous
GVHD is less clear. In one study, the transfer of cells lacking Fas-L
(CD95L) reduced the severity of murine cutaneous GVHD (Miwa
et al., 1999). In another study, recipient mice deficient in Fas (CD95)
showed increased severity of cutaneous GVHD (van den Brink et
358 Crit Rev Oral Biol Med 13(4):350-365 (2002)
al., 2000). An MMP inhibitor was recently shown to alleviate
GVHD pathology in the liver, intestine, and hematopoietic tissues
and to reduce weight loss and mortality in murine GVHD (Hattori
et al., 1999). Mast cells may undergo extensive degranulation dur-
ing the development of murine cutaneous GVHD (Claman, 1985).
Mast cell degranulation and epithelial cell damage preceded the
influx of effector lymphocytes in murine GVHD (Murphy et al.,
1994). In another study, mast-cell-deficient mice developed intesti-
nal GVHD that was indistinguishable from that in their mast-cell-
competent littermates (Newlands et al., 1990). Hence, the role of
mast cells in GVHD is unclear. Current studies in a murine model
may elucidate the genetic and cellular pathogenesis of mucocuta-
neous GVHD.
Keratinocyte Apoptosis 
and LC Maturation in OLP
Not all auto-reactive T-cells are deleted in the thymus (Gammon
and Sercarz, 1989). Why, then, do some individuals carrying
auto-reactive T-cells develop autoimmune disease while others
do not? The outcome of self-antigen presentation depends on the
activation state of the APC. To stimulate a T-cell response, den-
dritic cells (DCs) and presumably LCs must undergo a process of
terminal differentiation called “maturation”. Stimuli for DC and
LC maturation include inflammatory cytokines (IL-1b, TNF-a),
CD40L (CD154) expressed by activated T-cells, necrotic cells,
HSPs, nucleotides, reactive oxygen intermediates, neurotrans-
mitters, MMP-9, extracellular matrix degradation products,
mechanical trauma, various allergens, ion channel blockade, Fc
receptor aggregation, viral RNA, and bacterial lipopolysaccha-
ride (Steinman et al., 2000; Gallucci and Matzinger, 2001). DCs
and LCs endocytose apoptotic cells including keratinocytes and
migrate to the regional lymph nodes, where they present pep-
tides derived from the apoptotic cells on MHC classes I and II
(Albert et al., 1998a,b; Inaba et al., 1998; Rovere et al., 1998; Huang
et al., 2000). Under normal circumstances, APCs carrying self-
peptides derived from apoptotic cells do not receive a matura-
tion stimulus and therefore do not trigger an auto-reactive T-cell
response (Steinman et al., 2000; Gallucci and Matzinger, 2001).
Immature APCs may avoid activating self-reactive T-cells by
various means, including (i) failure to form MHC-peptide com-
plexes, (ii) absence of co-stimulatory molecule expression, or (iii)
direct killing of self-reactive T-cells (Suss and Shortman, 1996;
Steinman et al., 2000). Conversely, APC endocytosis of apoptotic
cells followed by APC maturation may activate self-reactive
CD4+ T-cells that differentiate into Th1 or Th2 phenotypes and
promote cell- or antibody-mediated autoimmune reactions. The
nature of the APC maturation stimulus (e.g., cytokines, CD40L,
necrotic cells, HSPs, etc.) may determine the outcome (Th1 vs.
Th2) of CD4+ T-cell activation.
Endocytosis of apoptotic vaginal keratinocytes by LCs dur-
ing the estrus cycle has been described in mice (Parr et al., 1991).
Physiological keratinocyte apoptosis in the normal oral mucosa is
associated with normal epithelial turnover (Birchall et al., 1995).
Oral LCs may endocytose apoptotic oral keratinocytes and
migrate to the regional lymph nodes. In the normal oral mucosa,
the LCs do not receive a maturation stimulus. Hence, physiolog-
ical oral keratinocyte apoptosis does not elicit an anti-ker-
atinocyte autoimmune T-cell response, even in the presence of
keratinocyte-specific T-cells. As discussed previously, OLP and
oral lichenoid lesions may be triggered or exacerbated by
mechanical trauma, viral infection, bacterial products, systemic
drugs, or contact allergens which up-regulate oral keratinocyte
HSP expression and stimulate an anti-HSP autoimmune T-cell
response (Sugerman et al., 1995). An alternative explanation is
that these exogenous agents and/or the up-regulated HSP itself
may stimulate oral LC maturation (Steinman et al., 2000; Gallucci
and Matzinger, 2001). In the regional lymph node, mature LCs
that have endocytosed apoptotic oral keratinocytes would then
activate keratinocyte-specific CD4+ T-cells. As discussed previ-
ously, the outcome (Th1 vs. Th2) of CD4+ T-cell activation may
depend on the nature of the maturation stimulus delivered to the
LC. The Th1 or Th2 cytokines released from the activated ker-
atinocyte-specific CD4+ helper T-cells would co-stimulate ker-
atinocyte-specific CD8+ T-cells or B-cells, resulting in local or
widespread cell- or antibody-mediated anti-keratinocyte autoim-
mune inflammation. The phenotype of the resultant oral mucos-
al pathology would depend on the precise keratinocyte peptide
presented by the mature LC and the cytokine profile (Th1 or Th2)
of the responding CD4+ helper T-cell. In this context, a basal ker-
atinocyte peptide triggering a Th1 response may activate anti-
keratinocyte auto-reactive CD8+ cytotoxic T-cells, resulting in
OLP. A keratinocyte desmosomal peptide (desmoglein-3) trigger-
ing a Th2 response may stimulate auto-reactive B-cell anti-
desmoglein-3 antibody production, resulting in pemphigus vul-
garis. A keratinocyte hemidesmosomal (BP-180) or basement
membrane (laminin 5) peptide triggering a Th2 response may
stimulate auto-reactive B-cell anti-BP-180 or anti-laminin 5 anti-
body production, resulting in cicatricial pemphigoid.
As discussed previously, a microbe or systemic drug may
provide the LC maturation signal. In this case, the activation of
anti-keratinocyte auto-reactive lymphocytes would cease
upon microbe clearance or drug withdrawal. Erythema multi-
forme triggered by herpes simplex virus or a systemic drug is
an example of this type of inflammation in the oral cavity.
Long-term autoimmune oral mucosal pathology (e.g., OLP,
pemphigus vulgaris, cicatricial pemphigoid) may result from
(i) failure to eliminate the LC maturation stimulus (e.g.,
microbe, rough restoration, sharp tooth, systemic drug), (ii)
persistence of mature LCs, or (iii) failure to suppress autoreac-
tive lymphocytes in the oral mucosa. Furthermore, once OLP
has been initiated, the combination of cell-mediated cytotoxici-
ty and various inflammatory cytokines would continue to pro-
vide both the apoptotic oral keratinocytes and the oral LC mat-
uration stimulus, thus contributing to lesion chronicity. Little
is known about the role of oral LCs and the regional lymphat-
ics in OLP lesion formation or chronicity. However, blockade
of oral LC maturation or migration to the regional lymph
nodes may prevent anti-keratinocyte auto-reactive T-cell acti-
vation and may thus be therapeutic in OLP.
In the case of oral mucosal GVHD, cytotoxic drugs or radi-
ation may provide both the apoptotic oral keratinocytes and the
oral LC maturation stimulus resulting in chronic oral lichenoid
lesions following allogeneic BMT. Although Grinspan’s syn-
drome (triad of OLP, IDDM, and hypertension) has been
described, little evidence supports a connection between IDDM
and OLP. The oral lichenoid lesions in Grinspan’s syndrome
may be triggered by the drugs used to treat IDDM or hyperten-
sion (Scully et al., 1998). However, recent studies have suggest-
ed that hyperglycemia-induced apoptosis may underlie the islet
b-cell loss (Donath et al., 1999), congenital malformations
(Moley et al., 1998), microangiopathy (Ho et al., 2000), neuropa-
thy (Delaney et al., 2001), retinopathy (Naruse et al., 2000), car-
diomyopathy (Dyntar et al., 2001), and nephropathy (Ortiz et al.,
1997) associated with IDDM. It is tempting to speculate that
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hyperglycemia may also trigger oral keratinocyte apoptosis and
stimulate oral LC maturation, thereby causing the oral lichenoid
lesions associated occasionally with IDDM. Similarly, paraneo-
plastic pemphigus, pemphigoid, and lichenoid lesions may
result from tumor cell apoptosis and APC maturation (possibly
stimulated by tumor-associated HSP) with subsequent anti-
body- and cell-mediated mucocutaneous autoimmune inflam-
mation (Setterfield et al., 1999; Allen and Camisa, 2000; Bowen et
al., 2000; Sauter et al., 2000).
Carcinogenesis in OLP
SCC arises occasionally at the site of a pre-existing OLP lesion,
although it is unlikely that OLP is inherently pre-malignant
(Eisenberg, 2000; Silverman, 2000). The cause of increased oral
cancer risk in OLP patients is unknown, although the oral
mucosa affected by OLP may be more sensitive to exogenous
mutagens in tobacco, alcohol, betel quid, and Candida albicans.
As discussed previously, some cases of malignant transforma-
tion of OLP lesions may represent an initial lichenoid response
to pre-existing tumor cells expressing elevated levels of HSP,
followed by the development of overt clinical and histological
malignancy. We recently identified TGF-b1 expression in the
subepithelial lymphocytic infiltrate in OLP (Khan et al., 2001,
submitted). T-cell-derived TGF-b1 may inhibit growth and
induce differentiation and apoptosis of oral mucosal ker-
atinocytes, thereby suppressing tumor formation (Flanders and
Roberts, 2001). T-cells in OLP also express IFN-g and TNF-a
(Simark-Mattsson et al., 1998, 1999; Khan et al., 2001, submitted),
while many studies have shown that TNF-a, IFN-g, and IL-12
inhibit tumor growth and metastasis (Aggarwal et al., 2001;
Billiau and Vanderbroeck, 2001; Esche et al., 2001). Hence, TGF-
b1, TNF-a, IFN-g, and IL-12 may inhibit carcinogenesis in OLP.
As discussed previously, TGF-b1 was expressed weakly by
keratinocytes in OLP (Khan et al., 2001, submitted). In previous
studies, mouse skin treated with the tumor promoter 12-
tetradecanoyl-phorbol-13-acetate showed high levels of TGF-b1
mRNA in the suprabasal epithelium (Akhurst et al., 1988).
Overexpression of TGF-b1 in mouse skin resulted in stage-
dependent protection from, or enhancement of, carcinogen-
induced tumorigenesis (Cui et al., 1996). In this context, ker-
atinocyte TGF-b1 expression may play a role in cancer develop-
ment in OLP. The chronic inflammatory response and simulta-
neous epithelial wound-healing response may increase the like-
lihood of cancer-forming gene mutations in OLP. This hypothe-
sis is supported by recent important findings linking chemical
mediators of T-cell inflammation to tumorigenesis. These stud-
ies showed that macrophage migration inhibitory factor (MIF)
stimulated tumor cell proliferation, while MIF neutralization
inhibited tumor growth (Takahashi et al., 1998; Chesney et al.,
1999; Shimizu et al., 1999). Importantly, MIF released from T-
cells and macrophages suppressed the transcriptional activity of
the p53 tumor suppressor protein (Hudson et al., 1999). As dis-
cussed previously, normal p53 function is central to the preven-
tion of many cancers, including oral SCC (Sugerman and
Savage, 1999). Blockade of keratinocyte p53 function by MIF
may allow growth-promoting gene mutations to go unchecked,
thus setting the stage for cancer development in OLP. MIF plays
an essential role in delayed-type hypersensitivity reactions,
although its role in OLP has not been reported (Bernhagen et al.,
1996). Our previous studies identified MMP-9 production by T-
cells in OLP (Zhou et al., 2001). MMP-9 derived from mast cells,
neutrophils, and macrophages promoted cutaneous carcinogen-
esis in a K14-HPV16 transgenic mouse model via paracrine
effects on oncogene-positive neoplastic cells (Coussens et al.,
2000). Hence, MIF, MMP-9, and keratinocyte TGF-b1 may pro-
mote carcinogenesis in OLP.
In summary, the integrated signal from various tumor
inhibitors (e.g., TGF-b1, TNF-a, IFN-g, IL-12) and promoters
(e.g., MIF, MMP-9, keratinocyte TGF-b1) may determine the sen-
sitivity of oral keratinocytes to exogenous mutagens and may
regulate tumor growth and metastasis following cancer forma-
tion in OLP. Of further interest, the level of TGF-b1 in OLP may
be pivotal in disease pathogenesis and outcomes. Inadequate
immunosuppression associated with low TGF-b1 activity may
promote hyperactive immune responses in OLP. In contrast,
high TGF-b1 activity may suppress antitumor immune respon-
ses and thus promote carcinogenesis in OLP. In more general
terms, endogenous and therapeutic immunosuppression may, at
first glance, appear beneficial in OLP. However, such immuno-
suppression may down-regulate antitumor immune responses
and increase the oral cancer risk in OLP patients. It is interesting
to note that SCC is more likely to develop in atrophic and erosive
OLP lesions that typically receive immunosuppressive treat-
ment. Clearly, much research is required to determine the total
impact of current immunosuppressive therapies in OLP. Future
therapies may down-regulate the hyperactive immune respon-
ses but maintain the antitumor immune responses in OLP.
A Unifying Hypothesis for 
the Pathogenesis of OLP
On the basis of our recent experimental findings, we propose
a unifying hypothesis implicating both antigen-specific and
non-specific mechanisms in the pathogenesis of OLP. A
lichen planus antigen is expressed in association with MHC
class I molecules on keratinocytes at the OLP lesion site [1]
(numbers in brackets refer to Fig. 2). Antigen-specific CD8+
cytotoxic T-lymphocytes (CTLs) are activated in the OLP
epithelium (possibly with help from Th1 CD4+ T-cells, as dis-
cussed previously) and trigger keratinocyte apoptosis via
secreted TNF-a [2], although roles for granzyme B and Fas
cannot be excluded at this stage. TNF-a may be activated and
released from the CTL surface by lesional MMPs. Activated
T-cells undergo intra-lesional clonal expansion and release
RANTES and other cytokines [3] that up-regulate mast cell
CCR1 expression and stimulate intra-lesional mast cell
migration and degranulation [4]. Degranulating mast cells
release TNF-a which up-regulates endothelial cell adhesion
molecule expression for lymphocyte adhesion and extravasa-
tion [5]. Mast cell TNF-a also up-regulates RANTES [6] and
MMP-9 [7] secretion by OLP lesional T-cells. Activated
lesional T-cells (and possibly keratinocytes) secrete
chemokines which attract extravasated lymphocytes toward
the OLP epithelium [8]. Degranulating mast cells release chy-
mase that damages the epithelial basement membrane direct-
ly [9] or indirectly via activation of MMP-9 secreted by OLP
lesional T-cells [10]. Epithelial basement membrane disrup-
tion facilitates the passage of lymphocytes into the OLP
epithelium [11] and denies keratinocytes a cell survival sig-
nal, resulting in further keratinocyte apoptosis [12].
Initial Events in OLP Lesion Formation
As discussed previously, keratinocyte antigen expression may
be the initial event in OLP lesion formation. Subsequently, the
lichen planus antigen is recognized by antigen-specific T-cells
circulating through the oral epithelium or T-cells attracted to
the oral epithelium by keratinocyte-derived chemokines.
Following antigen recognition and activation, T-cell CD40L
may stimulate oral LC maturation for subsequent antigen pre-
sentation. Keratinocyte antigen expression and chemokine
secretion in OLP may be stimulated by viral infection, bacteri-
al products, mechanical trauma, systemic drugs or contact sen-
sitivity. In this scenario, mast cell degranulation and other
non-specific mechanisms are downstream events in OLP
lesion formation. Conversely, mast cell degranulation may be
an initial event that disrupts the epithelial basement mem-
brane and stimulates oral keratinocyte antigen expression and
LC maturation. In this scenario, antigen-specific interactions
between keratinocytes and T-cells are downstream events in
OLP lesion formation. It is also possible that the initial event in
OLP lesion formation may vary from patient to patient.
However, following the initial event in a susceptible patient,
both antigen-specific and non-specific mechanisms continue
relentlessly, producing the chronic lesions recognized clinical-
ly and histologically as OLP. As is evident from this discus-
sion, the initial event in OLP lesion formation is unknown.
Current time-course studies in a murine model may elucidate
primary events and genetic regulation in OLP.
OLP Susceptibility
It is likely that some of the antigen-specific and non-specific
mechanisms described here for OLP occur together or in isola-
tion in many people without causing chronic lichenoid lesions.
For example, viral infection of the oral mucosa produces a T-cell
response that typically does not progress to OLP. Similarly,
mechanical trauma to the oral mucosa causes mast cell degran-
ulation that typically does not progress to OLP. So, what consti-
tutes OLP susceptibility? Since generalized atopy is not associ-
ated with OLP, it is unlikely that dysregulated mast cell degran-
ulation is central to OLP susceptibility. However, dysregulated
mast cell chymase or TNF-a secretion (independent of mast cell
degranulation) may be involved. In this context, OLP suscepti-
bility may result from a combination of factors, including dys-
regulated oral keratinocyte antigen expression, persistence of
mature oral LCs, circulating auto-reactive T-cells, and defective
immune suppressor activity following self-antigen recognition.
OLP Research Directions and Future Therapies
Many questions remain concerning the etiology and pathogen-
esis of OLP. What is the lichen planus antigen? Does the lichen
planus antigen vary from site to site or patient to patient? What
proportion of T-cells in OLP lesions are specific for the lichen
planus antigen? What is the initial event in OLP lesion forma-
tion? What roles do oral LCs and the regional lymphatics play
in OLP lesion formation and chronicity? What triggers ker-
atinocyte apoptosis in OLP? What constitutes OLP susceptibil-
ity? Answers to these questions may help produce a cure for
OLP. In the meantime, analysis of current data suggests that
blocking IL-12, IFN-g, TNF-a, RANTES, or MMP-9 activity or
up-regulating TGF-b1 activity in OLP may be therapeutic.
Conclusions
The pathogenesis of OLP may involve both antigen-specific and
non-specific mechanisms. Antigen-specific mechanisms in OLP
include antigen presentation by basal keratinocytes and anti-
gen-specific keratinocyte killing by CD8+ cytotoxic T-cells. Non-
specific mechanisms include mast cell degranulation and matrix
metalloproteinase activation in OLP lesions. The initial event in
OLP lesion formation and the factors that determine OLP sus-
ceptibility are unknown. Clearly, more work is required for a
full understanding of the etiology and pathogenesis of OLP.
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Figure 2. Unifying hypothesis for the pathogenesis of OLP. (A) A lichen
planus antigen is expressed in association with MHC class I molecules on
basal keratinocytes at the OLP lesion site [1]. Antigen-specific CD8+ cyto-
toxic T-lymphocytes (CTLs) are activated in the OLP epithelium (possibly
with help from Th1 CD4+ T-cells, as shown in Fig. 1) and trigger ker-
atinocyte apoptosis via secreted TNF-a binding the TNF-a receptor
(TNF-R1) [2], although roles for granzyme B and Fas cannot be exclud-
ed at this stage. TNF-a may be activated and released from the CTL sur-
face by lesional MMPs. (B) Activated T-cells undergo intra-lesional clon-
al expansion and release RANTES and other cytokines [3] that up-regu-
late mast cell CCR1 expression and stimulate intra-lesional mast cell
migration and degranulation [4]. Degranulating mast cells release TNF-
a, which up-regulates endothelial cell adhesion molecule expression for
lymphocyte adhesion and extravasation [5]. Mast cell TNF-a also up-
regulates RANTES [6] and MMP-9 [7] secretion by OLP lesional T-cells.
Activated lesional T-cells (and possibly keratinocytes) secrete chemokines
that attract extravasated lymphocytes toward the OLP epithelium [8].
Degranulating mast cells release chymase that damages the epithelial
basement membrane directly [9] or indirectly via activation of MMP-9
secreted by OLP lesional T-cells [10]. Epithelial basement membrane dis-
ruption facilitates the passage of lymphocytes into the OLP epithelium
[11] and denies keratinocytes a cell survival signal, resulting in further
keratinocyte apoptosis [12]. (A) Represents the boxed area in (B).
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